Turalio — CareFirst (Caremark)
Tenosynovial giant cell tumor (TGCT)
Initial criteria
- Member is an adult.
- Turalio will be used as a single agent.
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months